Vancouver’s Precision NanoSystems announced today that it has received a contribution of $25.1 million through the Strategic Innovation Fund (SIF).
This contribution will support a $50.2-million project to establish a biomanufacturing centre in Vancouver dedicated to the production of ribonucleic acid (RNA) lipid nanoparticle vaccines and genetic medicines.
The centre will support the Government of Canada’s national biomanufacturing strategy to expand production capacity of critical medicines for the prevention and treatment of diseases such as COVID-19.
Precision NanoSystems is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases.
Leave a Reply